Analyzing the genetics and smoking habits of more than half a million people has shed new light on the complexities of controlling blood pressure, according to a study led by researchers at Washington University School of Medicine in St. Louis.
UC Davis pathologist Hooman Rashidi is an expert in blood disorders but also a computer programmer. He has married the two disciplines and created must-have learning tools for medical students and residents. His latest is HemeQuiz1, a medical student training app.
New data from the University of Illinois at Chicago suggest that the guidelines used to evaluate an individual’s peak blood pressure response during cardiopulmonary exercise testing, which were last updated in 1996 and help doctors screen for hypertension and cardiovascular disease, may need to be revised.
Cholesterol in muscular dystrophy; synergy between alcohol and hepatitis in cholesterol levels; bacterial lipids in healthy arteries.
A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer. In a trial initiated and led by the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, tumors shrunk in 34 out of 35 patients who took the drug, and more than half of those patients saw the tumor size decrease by more than 30 percent.
One of the greatest health threats to children with sickle cell anemia is getting a dangerous bacterial infection — but most are not receiving a key medication to reduce the risk, a new study suggests.
New oncology leaders for Rutgers Cancer Institute of New Jersey at University Hospital in Newark have been named, further enhancing the facility’s expertise and ability to deliver National Cancer Institute (NCI)-designated Comprehensive Cancer Center services to the greater Essex County region.
Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer.
• In generally healthy older men, slightly lower sodium levels in the blood were related to both cognitive impairment and declines in cognitive function over time. • Additional studies are needed to determine whether correction of lower serum sodium may influence cognition in older adults.
Researchers at the University of Maryland School of Medicine have uncovered genetic mutations that may explain why people with high levels of high-density lipoprotein (HDL) cholesterol, the “good cholesterol,” have a reduced risk of coronary heart disease.
Results of a phase II study presented at the recent American Society of Hematology Annual Meeting shows the best outcomes to date for older Hodgkin lymphoma patients treated with brentuximab vedotin before and after AVD chemotherapy. A presenting author from Rutgers Cancer Institute of New Jersey shares details.
Indiana University researchers have found that certain molecules -- several of which are currently under clinical trial -- are able to "crack" the protective shell of the hepatitis B virus, suggesting it may be possible to attack the virus after its already taken hold in the body. There is currently no cure for the virus, which can cause liver failure and cancer.
Researchers have detailed, for the first time, the normal human transcriptome of the blood-nerve barrier. This barrier — a tight covering of endothelial cells — maintains the microenvironment of peripheral nerves. Knowledge of the transcriptome will aid research in peripheral nerve disease.
Moffitt Cancer Center researchers are trying to identify new drug targets to reduce the risk of GVHD. Their new study, published in the Proceedings of the National Academy of Sciences, shows a drug that targets the protein JAK2 may reduce the risk of GVHD.
UCLA researchers, in collaboration with the University of Iowa, discovered the contribution of a specific gene in the proper development of blood cells that give rise to hematopoietic stem cells. The findings identify a potential target for the development of treatments for some types of leukemia, anemia and other blood disorders.
VF Bob is a new campaign launched by the Vasculitis Foundation to honor the late Bob Sahs, one of the organization's greatest awareness advocates. The goal of the campaign is to both spread awareness about autoimmune vasculitis, and to promote the work of the Vasculitis Foundation to support patients and fund research into vasculitis.
Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia (ALL), reveal that children and young adults continued to show high rates of durable, complete remission of their disease. Most side effects were short-lived and reversible.
Results of the global, multicenter, pivotal phase 2 study that led to the first FDA approval of a gene therapy/cell therapy approach known as CAR T-cell therapy, were published today in the New England Journal of Medicine.
Researchers studied blood samples taken from patients diagnosed with sepsis and found that elevated chlorinated lipids predicted whether a patient would go on to suffer acute respiratory distress symptom (ARDS) and die within 30 days from a lung injury.
Healthy Eating Could Decrease Risk of Vertebral Fractures, Especially in Women
Castleman disease, a rare disorder of the lymph nodes and related tissues, was identified and named more than a half-century ago but, until recently, no one had written a book exclusively about it. Frits van Rhee, M.D., Ph.D., professor of medicine and director of developmental and translational medicine at the Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS), has changed that.
A diet created by researchers at Rush University Medical Center may help substantially slow cognitive decline in stroke survivors, according to preliminary research presented on Jan. 25, at the American Stroke Association’s International Stroke Conference 2018 in Los Angeles. The finding are significant because stroke survivors are twice as likely to develop dementia compared to the general population.
UCLA scientists found that boosting mice's cholesterol levels spurred intestinal stem cells to divide more quickly, enabling tumors to form faster. The study identifies a new drug target for colon cancer treatment.
A new anti-cancer strategy wields light as a precision weapon. Unlike traditional light therapy — which is limited to the skin and areas accessible with an endoscope — this technique can target and attack cancer cells that have spread deep inside the body, according to researchers at Washington University School of Medicine in St. Louis.
UVA has discovered an unknown biological process that controls the production of red blood cells, which carry oxygen to the body. The discovery could help doctors develop new treatments for anemia, which affects millions.
Rutgers Cancer Institute of New Jersey is now recognized as a Center of Excellence by the Myelodysplastic Syndromes (MDS) Foundation in the research, diagnosis and treatment of MDS disorders.
New findings could change how iron metabolism in the human body is understood, and open new horizons for research and therapeutics for inflammatory diseases and neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease.
Patients with monoclonal gammopathy of undetermined significance are at risk of progressing to multiple myeloma or a related cancer ─ even after 30 years of stability. These are the findings of a study by Mayo Clinic researchers published in the Wednesday, Jan. 17, issue of the New England Journal of Medicine.
Using Oak Ridge National Laboratory's Titan supercomputer, a team led by Brown University’s George Karniadakis devised a multiscale model of sickle cell disease that captures what happens inside a red blood cell affected by the disease.
In treating stroke patients, every minute counts. A drug called rtPA sometimes can stop a stroke in its tracks. Now a Loyola Medicine study has found that having a pharmacist at the patient's bedside can reduce the time it takes to administer rtPA by a median of 23.5 minutes.
A rare glimpse into the prior authorization requirements implemented by public and private insurance providers across the country has found substantial administrative burden for a new class of medications for patients with high cholesterol that places them at high risk for heart attack or stroke. So-called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are self-injected medications approved for individuals with a genetic condition called familial hypercholesterolemia (FH) and those with atherosclerotic cardiovascular disease (ASCVD) who have high cholesterol despite receiving traditional statin medications and other treatments. Results of the study are published in Circulation: Cardiovascular Quality and Outcomes.
Certain head and neck cancers that are positive for high-risk types of human papillomavirus (HPV) have a better prognosis and may need less aggressive treatment.
Defects in mitochondria, the tiny structures that power our cells by functioning as biological batteries, cause an array of complex, often life-threatening disorders that can affect any and all organs and systems. In the absence of validated, effective drug treatments, patients with mitochondrial disease often take a variety of vitamins and supplements, substances that are largely unstandardized, unregulated, and unproven. A group of medical experts recommend performing systematic scientific studies to test precise nutritional interventions for patients.
A common, inexpensive drug that is used to prevent heart attacks and lower blood pressure may also help melanoma patients live longer.
A study led by St. Jude Children’s Research Hospital found germline variations in a key tumor suppressor gene that may prompt changes in treatment and follow-up care for certain high-risk leukemia patients
Scientists have sequenced the complete genome of an ancient strain of Hepatitis B, shedding new light on a pathogen that today kills nearly one million people every year. The findings, based on data extracted from the mummified remains of a small child buried in Naples, Italy, confirm the idea that HBV has existed in humans for centuries.
A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which will be published January 4 in the Journal of Experimental Medicine, reveals that ibrutinib has a diminished capacity to delocalize and kill tumor cells expressing an adhesive protein called CD49d, but combining ibrutinib treatment with drugs that block CD49d activation could prevent the tumor cells from sheltering in lymphoid organs.
In a commentary published in the Jan. 4 issue of the New England Journal of Medicine, UC Davis researcher William Murphy expressed cautious optimism about efforts to genetically engineer hematopoietic stem cells (HSCs) to temporarily resist cell death during transplantation. While these gene therapy approaches could dramatically improve patient outcomes, Murphy argues that their risks must be carefully studied in diverse models.
Donating blood is a tangible way to help people who are struggling with serious health conditions, yet many people may not think about it or make time for it.
Jonathan A. Epstein, MD, executive vice dean and chief scientific officer of Penn Medicine, has received a National Heart, Lung, and Blood Institute (NHLBI) Outstanding Investigator Award. The highly competitive award provides long-term support to “an experienced investigator with an outstanding record of research productivity.” In issuing the award, the NHLBI, which is part of the National Institutes of Health, described Epstein as “an outstanding, pioneering investigator” and “a gold standard role model for physician-scientists in the field.”
Half of sepsis survivors never fully recover; Dr. Derek Angus lays out an approach to change that.
Mount Sinai researchers have discovered a new drug combination that could provide the first targeted therapy for some of the deadliest cancers, as well as molecular predictors of tumor response to the therapy, according to a study published in Cell Reports in January.
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
In this month’s release, find new embargoed research that links increased hepatitis C numbers to the opioid epidemic, shows Medicaid expansion increasing cancer diagnoses, the ACA expanding breastfeeding and the prevalence of osteoarthritis growing
Research to develop and test an intervention that reduces the threat of this health problem for women of childbearing age
Researchers at the University of Georgia have identified several new genes that influence how the body regulates blood pressure.
Hackensack Meridian Health Hackensack University Medical Center is among the first in the tri-state region and the first in Bergen County, New Jersey to offer an innovative new treatment that prevents stroke in patients with blocked carotid arteries, the major blood vessels that deliver blood to the brain.
Below is the December tip sheet from Fred Hutchinson Cancer Research Center. Story ideas include new research on leukemia therapies, racial disparities in end-of-life care, an experimental drug for pancreatic cancer and more.
Mayo Clinic has been named a Center of Excellence by Angioma Alliance for treatment and research into cerebral cavernous angiomas.
Un estudio de Mayo Clinic descubrió que entre los obstáculos para que los pacientes se sometan al trasplante de células madre como parte del tratamiento para el mieloma múltiple están la educación, el seguro de salud y el acceso a atención médica en una institución con gran volumen de pacientes.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right